Compare Moody's Corporation (MCO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Novo Nordisk A/S — how do they compare? Moody's Corporation trades at $462.95 (market cap $79.44B), while Novo Nordisk A/S trades at $38.44 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.1× Moody's Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Novo Nordisk A/S for 116 Days on average.
| MCO | NVO | |
|---|---|---|
Market Cap | $79.44B | $165.31B |
Volume | 526,684 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $539.61 | $63.98 |
52-Week Low | $412.23 | $35.29 |
Typical Hold Time | 132 Days | 116 Days |
Enterprise Value | $85.46B | $179.56B |
Dividend Yield | 0.9% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $462.10, up 2.77% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals with 34.25% net margins and 80.15% ROE, though technical indicators signal near-term bearish pressure. Recent strategic moves include expanding Asia-Pacific presence through a PhilRatings stake and new credit risk product launches.
Outlook remains positive given consistent earnings beats and analyst consensus target of $536.40 (16% upside). Key risks include high valuation multiples (P/E 29.1) and potential macroeconomic sensitivity affecting credit rating demand. Institutional sentiment leans bullish with 56% buy ratings supporting long-term growth thesis.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
